Stillwater Capital Advisors LLC increased its position in Merck & Company, Inc. (NYSE:MRK) by 0.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 195,395 shares of the company’s stock after purchasing an additional 1,545 shares during the quarter. Merck & makes up 3.2% of Stillwater Capital Advisors LLC’s portfolio, making the stock its 9th biggest position. Stillwater Capital Advisors LLC’s holdings in Merck & were worth $12,523,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the stock. Trust Co increased its position in Merck & by 2.8% in the first quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after purchasing an additional 1,852 shares during the period. Catawba Capital Management VA increased its position in Merck & by 5.9% in the second quarter. Catawba Capital Management VA now owns 59,138 shares of the company’s stock worth $3,790,000 after purchasing an additional 3,312 shares during the period. Lau Associates LLC acquired a new stake in Merck & in the second quarter worth about $4,139,000. American National Bank increased its position in Merck & by 4.1% in the second quarter. American National Bank now owns 6,067 shares of the company’s stock worth $389,000 after purchasing an additional 241 shares during the period. Finally, Pioneer Trust Bank N A OR increased its position in Merck & by 4.3% in the second quarter. Pioneer Trust Bank N A OR now owns 7,760 shares of the company’s stock worth $497,000 after purchasing an additional 320 shares during the period. Hedge funds and other institutional investors own 73.02% of the company’s stock.
Merck & Company, Inc. (NYSE MRK) traded up 0.06% during midday trading on Friday, reaching $66.16. The company’s stock had a trading volume of 14,685,767 shares. The firm has a 50 day moving average of $63.41 and a 200 day moving average of $63.72. Merck & Company, Inc. has a 52-week low of $58.29 and a 52-week high of $66.80. The firm has a market cap of $180.44 billion, a P/E ratio of 35.82 and a beta of 0.81.
Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 earnings per share. Analysts anticipate that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.84%. Merck &’s payout ratio is currently 76.11%.
COPYRIGHT VIOLATION NOTICE: “Merck & Company, Inc. (MRK) is Stillwater Capital Advisors LLC’s 9th Largest Position” was posted by Equities Focus and is owned by of Equities Focus. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.equitiesfocus.com/2017/09/17/merck-company-inc-mrk-is-stillwater-capital-advisors-llcs-9th-largest-position.html.
A number of analysts recently commented on the company. BidaskClub lowered Merck & from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. BMO Capital Markets reiterated an “outperform” rating and issued a $73.00 price objective (down from $74.00) on shares of Merck & in a research report on Monday, July 24th. Citigroup Inc. set a $65.00 price objective on Merck & and gave the stock a “hold” rating in a research report on Wednesday, July 5th. Zacks Investment Research lowered Merck & from a “buy” rating to a “hold” rating in a research report on Thursday, May 25th. Finally, Jefferies Group LLC reiterated a “sell” rating and issued a $51.00 price objective on shares of Merck & in a research report on Wednesday, May 24th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $70.00.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.